{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:12:10Z","timestamp":1787955130217,"version":"build-2784847793"},"reference-count":75,"publisher":"American Association for Cancer Research (AACR)","issue":"21","funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["PDF16376814"],"award-info":[{"award-number":["PDF16376814"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD CDMRP","doi-asserted-by":"publisher","award":["BC171657"],"award-info":[{"award-number":["BC171657"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50 CA168504"],"award-info":[{"award-number":["P50 CA168504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50 CA165962"],"award-info":[{"award-number":["P50 CA165962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R35 CA210057"],"award-info":[{"award-number":["R35 CA210057"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Small-molecule targeted therapies have demonstrated outstanding potential in the clinic. These drugs are designed to minimize adverse effects by selectively attacking cancer cells while exerting minimal damage to normal cells. Although initial response to targeted therapies may be high, yielding positive response rates and often improving survival for an important percentage of patients, resistance often limits long-term effectiveness. On the other hand, immunotherapy has demonstrated durable results, yet for a limited number of patients. Growing evidence indicates that some targeted agents can modulate different components of the antitumor immune response. These include immune sensitization by inhibiting tumor cell\u2013intrinsic immune evasion programs or enhancing antigenicity, as well as direct effects on immune effector and immunosuppressive cells. The combination of these two approaches, therefore, has the potential to result in synergistic and durable outcomes for patients. In this review, we focus on the latest advances on integrating immunotherapy with small-molecule targeted inhibitors. In particular, we discuss how specific oncogenic events differentially affect immune response, and the implications of these findings on the rational design of effective combinations of immunotherapy and targeted therapies.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-19-2300","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T18:45:13Z","timestamp":1592937913000},"page":"5557-5566","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications"],"prefix":"10.1158","volume":"26","author":[{"given":"Johann S.","family":"Bergholz","sequence":"first","affiliation":[{"name":"1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheheryar","family":"Kabraji","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J.","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"2022061101365799300_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061101365799300_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2022061101365799300_bib3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022061101365799300_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"2022061101365799300_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061101365799300_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2022061101365799300_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"2022061101365799300_bib8","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC oncogene is a global regulator of the immune response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"},{"key":"2022061101365799300_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc Cooperates with Ras by Programming Inflammation and Immune Suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"},{"key":"2022061101365799300_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"2022061101365799300_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"2022061101365799300_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2022061101365799300_bib13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib14","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","article-title":"Lung cancer subtypes generate unique immune responses","volume":"197","author":"Busch","year":"2016","journal-title":"J Immunol"},{"key":"2022061101365799300_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2022061101365799300_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2022061101365799300_bib17","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022061101365799300_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to Anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"2022061101365799300_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"2022061101365799300_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to t cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022061101365799300_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"2022061101365799300_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature09677","article-title":"SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression","volume":"470","author":"Ding","year":"2011","journal-title":"Nature"},{"key":"2022061101365799300_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2022061101365799300_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib26","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061101365799300_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell Activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022061101365799300_bib31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061101365799300_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2022061101365799300_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2004","journal-title":"Nat Med"},{"key":"2022061101365799300_bib34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-15-2770","article-title":"STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis","volume":"76","author":"Jones","year":"2016","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061101365799300_bib36","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/0008-5472.CAN-10-3304","article-title":"A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-\u03baB in tumors","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3389\/fimmu.2018.01823","article-title":"Cancer cells exploit notch signaling to redefine a supportive cytokine milieu","volume":"9","author":"Colombo","year":"2018","journal-title":"Front Immunol"},{"key":"2022061101365799300_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"2022061101365799300_bib39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"2022061101365799300_bib40","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib41","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI66236","article-title":"Host immunity contributes to the anti-melanoma activity of BRAF inhibitors","volume":"123","author":"Knight","year":"2013","journal-title":"J Clin Invest"},{"key":"2022061101365799300_bib42","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/2326-6066.CIR-14-0074","article-title":"BRAF inhibition alleviates immune suppression in murine autochthonous melanoma","volume":"2","author":"Steinberg","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061101365799300_bib43","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","article-title":"BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy","volume":"72","author":"Koya","year":"2012","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib44","doi-asserted-by":"crossref","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022061101365799300_bib45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061101365799300_bib46","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"2022061101365799300_bib47","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"2022061101365799300_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"2022061101365799300_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments anti-tumor immunity by enhancing T Cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib50","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1038\/s41586-019-1351-8","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance","volume":"571","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"2022061101365799300_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"2022061101365799300_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.1059","article-title":"Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab","author":"Tolaney","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib53","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep"},{"key":"2022061101365799300_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"2022061101365799300_bib55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"2022061101365799300_bib56","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"2022061101365799300_bib58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2326-6066.CIR-18-0071","article-title":"PARP1 suppresses the transcription of PD-L1 by poly(ADP-Ribosyl)ating STAT3","volume":"7","author":"Ding","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2022061101365799300_bib59","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with parp inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061101365799300_bib60","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061101365799300_bib61","doi-asserted-by":"crossref","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2022061101365799300_bib62","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"2022061101365799300_bib63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2018.04.555","article-title":"An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)","volume":"149","author":"Drew","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2022061101365799300_bib64","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022061101365799300_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3013","article-title":"A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors","author":"Friedlander","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib66","article-title":"A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC)","author":"Karzai","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib67","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.1011","article-title":"TOPACIO\/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial","author":"Vinayak","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib69","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity","author":"Disis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2022061101365799300_bib71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022061101365799300_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5511","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study","author":"Matulonis","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib73","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"2022061101365799300_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5513","article-title":"Pembrolizumab in patients (pts) with PD-L1\u2013positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028","author":"Varga","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061101365799300_bib75","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/26\/21\/5557\/2063614\/5557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/26\/21\/5557\/2063614\/5557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T13:36:33Z","timestamp":1654954593000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/26\/21\/5557\/82925\/Integrating-Immunotherapy-and-Targeted-Therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":75,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2300","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}